Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.48 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162822 | 0.86 | EHMT2 (0.50) | ALDH1A1EHMT2EHMT1APOBEC3GKMT2A | |
| SCHEMBL10347772 | 0.83 | EHMT2 (0.47) | ALDH1A1EHMT2EHMT1APOBEC3GKMT2A | |
| SCHEMBL28950323 | 0.83 | LMNA (0.47) | ALDH1A1EHMT2EHMT1APOBEC3GKMT2A | |
| SCHEMBL1607376 | 0.79 | LMNA (0.55) | ALDH1A1EHMT2EHMT1APOBEC3GKMT2A | |
| SCHEMBL28254695 | 0.76 | LMNA (0.52) | ALDH1A1EHMT2EHMT1APOBEC3GKMT2A | |
| Bicarbonate SCHEMBL16975006 | 0.75 | EHMT2 (0.77) | ALDH1A1EHMT2EHMT1APOBEC3GKMT2A | |
| SCHEMBL1360606 | 0.74 | EHMT2 (0.61) | ALDH1A1EHMT2EHMT1APOBEC3GKMT2A | |
| SCHEMBL9846767 | 0.74 | ALPI (0.47) | ALDH1A1KMT2AMAPTLMNAPOLB | |
| SCHEMBL535803 | 0.74 | LMNA (0.50) | ALDH1A1EHMT2EHMT1APOBEC3GKMT2A | |
| SCHEMBL1479297 | 0.74 | ALDH1A1 (0.55) | ALDH1A1EHMT2EHMT1APOBEC3GKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108507-B | Process for preparing diaryl thiohydantoin compounds | 阿拉贡药品公司 | 2024-05-28 | — | — | CN | claimed |
| CN-111620849-B | Process for preparing diaryl thiohydantoin compounds | 阿拉贡药品公司 | 2023-11-14 | — | — | CN | claimed |
| CN-113264859-B | Naphthalene sulfonamide isothiocyanate bifunctional micromolecules as well as preparation method and application thereof | 宁夏医科大学 | 2023-02-07 | — | — | CN | claimed |
| CN-113264859-A | Naphthalene sulfonamide isothiocyanate bifunctional micromolecules as well as preparation method and application thereof | 宁夏医科大学 | 2021-08-17 | — | — | CN | claimed |
| CN-111620849-A | Process for preparing diarylthiohydantoin compounds | 阿拉贡药品公司 | 2020-09-04 | — | — | CN | claimed |
| CN-107108553-B | Process for preparing diarylthiohydantoin compounds | 阿拉贡药品公司 | 2020-04-28 | — | — | CN | claimed |
| US-12570647-B2 | Amino benzothiazole compounds for treatment of antibiotic resistant bacteria | SAINT LOUIS UNIVERSITY (US) | 2026-03-10 | — | — | US | disclosed |
| CN-111295444-B | Polynomial coding for oligonucleotide-directed combinatorial chemistry | 哈斯达克科学公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-107108507-B | Process for preparing diaryl thiohydantoin compounds | 阿拉贡药品公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-111620849-B | Process for preparing diaryl thiohydantoin compounds | 阿拉贡药品公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-115820806-A | Combinatorial synthesis of oligonucleotide directed and recorded coded probe molecules | 哈斯达克科学公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-113264859-B | Naphthalene sulfonamide isothiocyanate bifunctional micromolecules as well as preparation method and application thereof | 宁夏医科大学 | 2023-02-07 | — | — | CN | disclosed |
| CN-109312492-B | Combinatorial synthesis of oligonucleotide directed and recorded coded probe molecules | 哈斯达克科学公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-1995003316-A3 | SOLUTION AND SOLID PHASE STEREOCONTROLLED GLYCOSIDATION | HANESSIAN STEPHEN (CA) | 1995-03-30 | — | — | WO | disclosed |
| WO-1995003316-A2 | SOLUTION AND SOLID PHASE STEREOCONTROLLED GLYCOSIDATION | HANESSIAN STEPHEN (CA) | 1995-02-02 | — | — | WO | disclosed |
| WO-1995003316-A2 | SOLUTION AND SOLID PHASE STEREOCONTROLLED GLYCOSIDATION | HANESSIAN STEPHEN (CA) | 1995-02-02 | — | — | WO | disclosed |
| EP-0480939-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5273975-A | Heterocyclic amines having central nervous system activity | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0480939-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY. | UPJOHN CO (US) | 1992-04-22 | — | — | EP | disclosed |
| WO-1990015058-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570647-B2 | Amino benzothiazole compounds for treatment of antibiotic resistant bacteria | BCAT1, BCAT2, IL4I1 | ALDH1A1 1173/4885EHMT2 3055/4885EHMT1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.